Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CLDI · NYSE · Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics (CLDI) · oqro.io/stocks/CLDI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.4775−0.0275 (−5.45%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 8 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 17 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Allan Camaisa (Director) sold ~$1.2K of Calidi Biotherapeutics
Automatic saleInsider buying
Traded Aug 21, 2025 · filed 5 days later
A Calidi Biotherapeutics director paid $250K out of pocket for Calidi Biotherapeutics shares. 3 other people at Calidi Biotherapeutics bought some too, in the same month. Shares held went up 2212% with this purchase.
Insider buying
Traded Aug 21, 2025 · filed 5 days later
A Calidi Biotherapeutics director paid $150K out of pocket for Calidi Biotherapeutics shares. 3 other people at Calidi Biotherapeutics bought some too, in the same month. Shares held went up 6614% with this purchase.
Insider buying
Traded Aug 21, 2025 · filed 5 days later
The CEO of Calidi Biotherapeutics paid $50K out of pocket for Calidi Biotherapeutics shares. 3 other people at Calidi Biotherapeutics bought some too, in the same month.
Insider buying
Traded Aug 21, 2025 · filed 5 days later
The CFO of Calidi Biotherapeutics paid $5K out of pocket for Calidi Biotherapeutics shares. 3 other people at Calidi Biotherapeutics bought some too, in the same month.
Insider selling
Traded Dec 17, 2024 · filed 2 days laterNot reported under a pre-arranged trading plan
The CEO of Calidi Biotherapeutics sold $16K of Calidi Biotherapeutics shares. The filing does not indicate a pre-arranged trading plan.
0 open-market purchases and 0 open-market sales by insiders of CLDI between Feb 25, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 13, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 13, 2026 | None | None | None |
| Aug 13, 2026 | None | None | None |
| May 14, 2026 | None | None | None |
| Mar 27, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies